Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ITM 91

Next Previous
Drug Profile

ITM 91

Alternative Names: [177Lu]Lu-DPI-4452; CAIX-targeted radiopharmaceuticals; Debio 0228; Debio 0228 programme; ITM-91; Lutenium-177 DPI 4452; Targeted CAIX Radiotherapy - Debiopharm /3B Pharmaceuticals

Latest Information Update: 19 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator 3B Pharmaceuticals
  • Developer 3B Pharmaceuticals; Debiopharm
  • Class Antineoplastics; Cyclic peptides; Diagnostic agents; Imaging agents; Peptides; Peptidomimetics; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Colorectal cancer; Pancreatic cancer; Renal cell carcinoma
  • Preclinical Cancer

Most Recent Events

  • 12 Sep 2024 ITM in-licenses ITM 91 from Debiopharm
  • 14 Mar 2023 Phase-I/II clinical trials in Colorectal cancer (In adults, In the elderly, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in France (IV) (NCT05706129)
  • 14 Mar 2023 Phase-I/II clinical trials in Pancreatic cancer (In adults, In the elderly, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in France (IV) (NCT05706129)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top